A Study To Investigate The Safety And Possible Clinical B... | NCT01240915 | Trialant
NCT01240915
Sponsor
Pfizer
Status
Completed
Last Update Posted
Feb 23, 2016Estimated
Enrollment
105Actual
Phase
Phase 2
Conditions
Colitis, Ulcerative
Interventions
placebo
MultiStem low dose
placebo
MultiStem low dose
placebo
MultiStem high dose
placebo
MultiStem high dose
placebo
MultiStem high dose
placebo
MultiStem high dose
Countries
United States
Belgium
Canada
Germany
Hungary
Italy
Slovakia
Sweden
Protocol Section
Identification Module
NCT ID
NCT01240915
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
B3041001
Secondary IDs
ID
Type
Description
Link
2010-022766-27
EudraCT Number
Brief Title
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
Official Title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis
Acronym
Not provided
Organization
PfizerINDUSTRY
Status Module
Record Verification Date
Jan 2016
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Feb 2011
Primary Completion Date
Nov 2014Actual
Completion Date
Nov 2014Actual
First Submitted Date
Nov 10, 2010
First Submission Date that Met QC Criteria
Nov 10, 2010
First Posted Date
Nov 15, 2010Estimated
Results Waived
Not provided
Results First Submitted Date
Nov 20, 2015
Results First Submitted that Met QC Criteria
Jan 26, 2016
Results First Posted Date
Feb 23, 2016Estimated
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Jan 26, 2016
Last Update Posted Date
Feb 23, 2016Estimated
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
PfizerINDUSTRY
Collaborators
Name
Class
Healios K.K.
INDUSTRY
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Not provided
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
MultiStem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. Factors expressed by MultiStem cells are believed to reduce inflammation and regulate immune system function, protect damaged or injured cells and tissue, promote formation of new blood vessels, and augment tissue repair and healing. MultiStem cell treatment resulted in significant efficacy in a mouse model of Graft versus Host Disease with almost complete reversal of gastrointestinal pathology (similar to pathology that would be expected in Ulcerative Colitis). These data, together with safety data generated in 2 other clinical trials, suggest that MultiStem has the potential to be a new treatment option for patients with ulcerative colitis. This is the first study of MultiStem in this patient population and will cautiously explore the safety/toleration and potential benefit of this new treatment in patients with moderate to severe disease.
Detailed Description
Not provided
Conditions Module
Conditions
Colitis, Ulcerative
Keywords
safety efficacy MultiStem(r) moderate to severe Ulcerative Colitis
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
105Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Cohort 1
Experimental
The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 & 2).
Drug: placebo
Drug: MultiStem low dose
Cohort 2
Experimental
This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.
Drug: placebo
Drug: MultiStem high dose
Cohort 3
Experimental
These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo.
Drug: placebo
Drug: MultiStem high dose
Interventions
Name
Type
Description
Arm Group Labels
Other Names
placebo
Drug
once every 7 days for 1- 3 doses
Cohort 1
MultiStem low dose
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8
Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding).
Baseline and Week 8
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 4
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
Baseline and Week 4
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 8
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
Baseline and Week 8
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.
Baseline up to Week 52
Number of Participants With Treatment-Emergent AEs by System Organ Class (SOC)
Secondary Outcomes
Measure
Description
Time Frame
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 12 and Week 16
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
Baseline, Week 12, Week 16
Number of Participants With Laboratory Test Abnormalities
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Subjects must have a documented diagnosis of ulcerative colitis at least 6 months prior to screening.
Subjects must have active moderate-to-severe ulcerative colitis based on Mayo score.
Subjects must have Modified Baron endoscopic score of at least 2 determined within 7 days of first dosing.
Subjects must have failed or be intolerant (as determined by the investigator) of at least one of the following treatments for UC: Oral corticosteroids, azathioprine or 6-mercaptopurine (6-MP), or anti-tumor necrosis factor (TNF) therapy, eg, infliximab or adalimumab.
Subjects must be on stable steroid doses.
Exclusion Criteria:
Subjects who have abnormal organ and marrow function.
Subjects with a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn's disease.
Subjects who meet Truelove-Witts criteria for severe ulcerative colitis.
Subjects receiving or who are expected to receive Infliximab or other biologic treatment within 8 weeks of the Day 1 study visit.
Subjects receiving or who are expected to receive Cyclosporine, mycophenolate, or tacrolimus within 4 weeks of the Day 1 study visit.
Accepts Healthy Volunteers
No
Sex
All
Sex/Gender Based
Not provided
Sex/Gender Description
Not provided
Minimum Age
18 Years
Maximum Age
Not provided
Standard Ages
AdultOlder Adult
Study Population
Not provided
Sampling Method
Not provided
Contacts/Locations Module
Central Contacts
Not provided
Overall Officials
Name
Affiliation
Role
Pfizer CT.gov Call Center
Pfizer
Study Director
Locations
Facility
Status
City
State
ZIP
Country
Contacts
University of California San Francisco
San Francisco
California
94115
United States
USCF Endoscopy Unit at Mount Zion
References Module
Citations
Not provided
See Also Links
Label
URL
To obtain contact information for a study center near you, click here.
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
FG001
Cohort 2: Placebo, MultiStem 750
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
5
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
No data available
No data is available for this block.
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
Intervention Browse Module
No data available
No data is available for this block.
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Not provided
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
Triple
Masking Description
Not provided
Who Masked
ParticipantInvestigatorOutcomes Assessor
Drug
1-3 doses
Cohort 1
placebo
Drug
Single dose at week 8
Cohort 1
MultiStem low dose
Drug
Single dose at week 8
Cohort 1
placebo
Drug
Single dose Day 1
Cohort 2
MultiStem high dose
Drug
Single dose Day 1
Cohort 2
placebo
Drug
Single dose at week 8
Cohort 2
MultiStem high dose
Drug
Single dose at week 8
Cohort 2
placebo
Drug
Single dose Day 1
Cohort 3
MultiStem high dose
Drug
Single dose Day 1
Cohort 3
placebo
Drug
Single dose at week 8
Cohort 3
MultiStem high dose
Drug
Single dose at week 8
Cohort 3
Baseline up to Week 52
Number of Treatment-Emergent AEs by Severity
The intensity grades were defined as follows: mild=does not interfere with participant's usual function; moderate=interferes to some extent with participant's usual function; severe=interferes significantly with participant's usual function.
Baseline up to Week 52
The total number of participants with laboratory test abnormalities with or without regard to baseline abnormality was assessed. Laboratory parameters included: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte sedimentation rate); chemistry (blood urea nitrogen and creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein; urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy (only if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase); other (follicle-stimulating hormone, human chorionic gonadotropin, stool microbiology, creatinine kinase, direct bilirubin, indirect bilirubin, gamma-glutamyl transferase, international normalized ratio.
Baseline up to Week 24
Number of Participants With Potentially Clinically Significant Vital Signs Findings
Vital signs assessment included pulse rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Criteria for vital sign values meeting potential clinical concern included: SBP <90 millimeters of mercury (mm Hg) and >=30 mm Hg increase/decrease from baseline, DBP <50 mm Hg and >=20 mm Hg increase/decrease from baseline, pulse rate <40 or >120 beats per minute (bpm),
Baseline up to Week 52
Fold Change From Baseline in Fecal Calprotectin at Weeks 4, 8, 12, and 16
Fecal calprotectin, a very stable marker, is a 36kDa calcium and zinc binding protein which is neutrophil-derived. It represents 60% of cytosolic proteins in granulocytes and is a measurement of neutrophil migration to the gastrointestinal tract.
Baseline, Weeks 4, 8, 12 and 16
Fold Change From Baseline in C-Reactive Protein (CRP) at Weeks 4, 8, 12, and 16
CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. CRP has a short half-life (19 hours) and therefore rises early after the onset of inflammation and rapidly decreases after resolution of the inflammation. It is induced by interleukin-6, TNF-alpha and other pro-inflammatory cytokines that are produced within the intestinal lamina propria.
Baseline, Weeks 4, 8, 12 and 16
Percentage of Participants With Rectal Bleeding Mayo Subscore of Zero at Weeks 4, 8, 12, and 16
Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes).
Week 4, 8, 12 and 16
Percentage of Participants in Endoscopic Remission at Week 8
Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding). Endoscopic remission is defined as modified Baron Endoscopic Score equal to 0.
Week 8
Percentage of Participants in Clinical Remission at Week 8
Clinical remission is defined as a total Mayo score of 2 points or lower, with no individual subscores exceeding 1 point.
Week 8
Percentage of Participants With Decrease From Baseline of at Least 1 Point in Rectal Bleeding Mayo Subscore at Weeks 4, 8, 12, and 16
Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes). A decrease from baseline score indicates improvement.
Baseline, Weeks 4, 8, 12 and 16
Percentage of Participants With Endoscopic Response at Week 8
Endoscopic response is defined as a decrease in modified Baron endoscopic score from baseline of at least 2 points.
Week 8
Percentage of Participants in Clinical Response at Week 8
Clinical response is defined as a decrease in total Mayo score from baseline of at least 3 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1.
Week 8
Change From Baseline in Total Mayo Scores at Week 8
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis, with total score ranging from 0 to 12. It consists of 4 subscores (stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and physician global assessment [PGA]), each graded from 0 to 3, with higher scores indicating more severe disease.
Baseline, Week 8
Change From Baseline in Partial Mayo Scores at Weeks 4, 8, 12, and 16
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo Score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. A Partial Mayo Score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Higher scores indicate more severe disease.
Baseline, Weeks 4, 8, 12 and 16
Change From Baseline in Biopsy Histology Scores at Week 8
A 15 to 25 centimeter (cm) biopsy sample of inflamed mucosal tissue was taken from the worst affected area and scored using the Riley Index. The Riley Index is a histologic scoring system for the assessment of the activity and severity of ulcerative colitis, ranging from 0 to 24. It consists of 6 histologic features (acute inflammatory cell infiltrate, crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, and crypt architectural irregularities), all scored on a 4-point scale (higher scores indicate more severe disease).
Baseline and Week 8
Change From Baseline in Patient-Reported Rectal Bleeding up to Week 16
Patient-reported diary data assessed the number of bowel movements (BM) per day when not having a flare and the presence of blood in the stools (rectal bleeding [RB]), if any.
Baseline and Week 16
San Francisco
California
94115
United States
Clinical Research of the Rockies
Lafayette
Colorado
80026
United States
Rocky Mountain Gastroenterology Associates, LLC
Lakewood
Colorado
80215
United States
Arapahoe Gastroenterology, PC
Littleton
Colorado
80120
United States
Metropolitan Gastroenterology Group, PC
Washington D.C.
District of Columbia
20006
United States
Gastroenterology Consultants of Clearwater
Clearwater
Florida
33756
United States
West Coast Endoscopy Center
Clearwater
Florida
33756
United States
Clinical Research of West Florida, Inc.
Clearwater
Florida
33765
United States
Borland-Groover Clinic
Jacksonville
Florida
32256
United States
Jacksonville Center for Endoscopy
Jacksonville
Florida
32256
United States
Miami Research Associates
South Miami
Florida
33143
United States
University of Chicago Medical Center
Chicago
Illinois
60637
United States
Cotton-O'Neil Clinical Research Center, Digestive Health
Topeka
Kansas
66606
United States
University of Louisville Healthcare Outpatient Center
Louisville
Kentucky
40202
United States
University of Louisville Hospital
Louisville
Kentucky
40202
United States
Metropolitan Gastroenterology Group, PC - Chevy Chase Clinical Research
Chevy Chase
Maryland
20815
United States
Endoscopic Microsurgery Associates, PA
Towson
Maryland
21204
United States
Clinical Research Institute of Michigan, LLC
Chesterfield
Michigan
48047
United States
Center for Digestive Health
Troy
Michigan
48098
United States
Utica Surgery Center
Utica
Michigan
48317
United States
Surgery Center of Columbia
Columbia
Missouri
65201
United States
Center for Digestive and Liver Diseases, Inc.
Mexico
Missouri
65265
United States
Present, Chapman, Steinlauf and Marion
New York
New York
10028
United States
Mount Sinai School of Medicine
New York
New York
10029
United States
Asher Kornbluth, MD PC
New York
New York
10128
United States
Charlotte Gastroenterology and Hepatology, PLLC
Charlotte
North Carolina
28207
United States
Wake Internal Medicine Consultants, Inc.
Raleigh
North Carolina
27612
United States
Wake Research Associates
Raleigh
North Carolina
27612
United States
Wake Forest University University Baptist Medical Center - Internal Medicine
Winston-Salem
North Carolina
27157
United States
Gastro One
Germantown
Tennessee
38138
United States
Vanderbilt University Medical Center
Nashville
Tennessee
37232-1375
United States
Digestive and Liver Disease Specialists
Norfolk
Virginia
23502
United States
Sentara Leigh Hospital
Norfolk
Virginia
23502
United States
Sentara Norfolk General Hospital
Norfolk
Virginia
23507
United States
McGuire DVAMC
Richmond
Virginia
23249
United States
University of Washington Medical Center
Seattle
Washington
98195
United States
Hopital Erasme / Gastroenterology
Brussels
1070
Belgium
Pfizer Clinical Research Unit
Brussels
1070
Belgium
University of Alberta Hospital
Edmonton
Alberta
T6G 2B7
Canada
Northern Alberta Clinical Trials and Research Center
Edmonton
Alberta
T6G 2C8
Canada
Zeidler Ledcor Centre - University of Alberta
Edmonton
Alberta
T6G 2X8
Canada
Maisonneuve-Rosemont Hospital
Montreal
Quebec
H1T 2M4
Canada
Agaplesion Markus Krankenhaus
Frankfurt am Main
60431
Germany
Universitaetsklinikum Halle
Halle
06120
Germany
Medizinische Hochschule Hannover
Hanover
30625
Germany
Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia
Budapest
1125
Hungary
Pandy Kalman Megyei Korhaz, III. sz. Belosztaly-Gasztroenterologia
Gyula
5700
Hungary
Karolina Korhaz Rendelointezet, Belgyogyaszat
Mosonmagyaróvár
9200
Hungary
Tolna Megyei Balassa Janos Korhaz / II. Belgyogyaszat
Szekszárd
7100
Hungary
Azienda Ospedaliera Luigi Sacco
Milan
20157
Italy
Azienda Ospedaliera di Padova
Padova
35128
Italy
Policlinico Universitario Agostino Gemelli
Roma
00168
Italy
Gastroenterologicke a hepatologicke oddelenie, V. interna klinika LFUK a UN Bratislava, Ruzinov
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
FG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
FG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
FG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
FG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
FG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
FG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
FG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
FG0002 subjects
FG0013 subjects
FG0022 subjects
FG0034 subjects
FG0046 subjects
FG00523 subjects
FG00625 subjects
FG00719 subjects
FG00821 subjects
COMPLETED
FG0000 subjects
FG0012 subjects
FG0022 subjects
FG0031 subjects
FG0042 subjects
FG00513 subjects
FG00617 subjects
FG00715 subjects
FG00813 subjects
NOT COMPLETED
FG0002 subjects
FG0011 subjects
FG0020 subjects
FG0033 subjects
FG0044 subjects
FG00510 subjects
FG0068 subjects
FG0074 subjects
FG0088 subjects
Type
Comment
Reasons
Adverse Event
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0031 subjects
FG0040 subjects
FG0052 subjects
FG0060 subjects
FG0070 subjects
FG0081 subjects
Lost to Follow-up
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0002 subjects
FG0011 subjects
FG0020 subjects
FG0032 subjects
FG004
Other
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Insufficient Clinical Response
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
The safety analysis set consisted of all participants who received at least 1 dose of study medication.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
BG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
BG002
Cohort 1: MultiStem 300 or MultiStem 300 (x3), Placebo
Participants received either a single dose of MultiStem 300 Million Cells infusion on Day 1 or 3 doses on Day 1, Week 1, and Week 2; followed by a single dose of placebo infusion at Week 8.
BG003
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
BG004
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
BG005
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
BG006
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
BG007
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
BG008
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0002
BG0013
BG0026
BG0036
BG00423
BG00525
BG00619
BG00721
BG008105
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00061.0± 7.1
BG00152.0± 7.0
BG00249.3± 14.1
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0000
BG0011
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8
Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding).
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint. Baseline observation carried forward (BOCF) was used for treatment failures.
Posted
Mean
Standard Deviation
scores on a scale
Baseline and Week 8
ID
Title
Description
OG000
Pooled MultiStem
All participants who received MultiStem 750 Million Cells infusion on Day 1 in Cohort 3.
OG001
Pooled Placebo
All participants who received placebo infusion on Day 1 in Cohort 3.
Units
Counts
Participants
OG00048
OG00140
Title
Denominators
Categories
Baseline
Title
Measurements
OG0003.13± 1.104
OG0013.10± 1.128
Change at Week 8
Title
Measurements
OG000
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Pooled MultiStem versus Pooled Placebo
ANCOVA
0.96
1-sided p-value
Mean Difference (Final Values)
0.40
Standard Error of the Mean
0.223
2-Sided
80
0.12
0.69
No
Superiority or Other
Primary
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 4
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.
Posted
Mean
Standard Deviation
scores on a scale
Baseline and Week 4
ID
Title
Description
OG000
Pooled MultiStem
All participants who received MultiStem 750 Million Cells infusion on Day 1 in Cohort 3.
OG001
Pooled Placebo
All participants who received placebo infusion on Day 1 in Cohort 3.
Units
Counts
Participants
OG000
Primary
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 8
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.
Posted
Mean
Standard Deviation
scores on a scale
Baseline and Week 8
ID
Title
Description
OG000
Pooled MultiStem
All participants who received MultiStem 750 Million Cells infusion on Day 1 in Cohort 3.
OG001
Pooled Placebo
All participants who received placebo infusion on Day 1 in Cohort 3.
Units
Counts
Participants
OG000
Primary
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.
The safety analysis population consisted of all participants who received at least 1 dose of study medication.
Posted
Number
participants
Baseline up to Week 52
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Primary
Number of Participants With Treatment-Emergent AEs by System Organ Class (SOC)
The safety analysis population consisted of all participants who received at least 1 dose of study medication.
Posted
Number
participants
Baseline up to Week 52
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
Primary
Number of Treatment-Emergent AEs by Severity
The intensity grades were defined as follows: mild=does not interfere with participant's usual function; moderate=interferes to some extent with participant's usual function; severe=interferes significantly with participant's usual function.
The safety analysis population consisted of all participants who received at least 1 dose of study medication.
Posted
Number
adverse events
Baseline up to Week 52
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Secondary
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 12 and Week 16
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.
Posted
Mean
Standard Deviation
scores on a scale
Baseline, Week 12, Week 16
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Secondary
Number of Participants With Laboratory Test Abnormalities
The total number of participants with laboratory test abnormalities with or without regard to baseline abnormality was assessed. Laboratory parameters included: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte sedimentation rate); chemistry (blood urea nitrogen and creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein; urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy (only if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase); other (follicle-stimulating hormone, human chorionic gonadotropin, stool microbiology, creatinine kinase, direct bilirubin, indirect bilirubin, gamma-glutamyl transferase, international normalized ratio.
The safety analysis population consisted of all participants who received at least 1 dose of study medication; n=the number of participants analyzed at that time point in the respective arms.
Posted
Number
participants
Baseline up to Week 24
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Secondary
Number of Participants With Potentially Clinically Significant Vital Signs Findings
Vital signs assessment included pulse rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Criteria for vital sign values meeting potential clinical concern included: SBP <90 millimeters of mercury (mm Hg) and >=30 mm Hg increase/decrease from baseline, DBP <50 mm Hg and >=20 mm Hg increase/decrease from baseline, pulse rate <40 or >120 beats per minute (bpm),
The safety analysis population consisted of all participants who received at least 1 dose of study medication.
Posted
Number
participants
Baseline up to Week 52
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Secondary
Fold Change From Baseline in Fecal Calprotectin at Weeks 4, 8, 12, and 16
Fecal calprotectin, a very stable marker, is a 36kDa calcium and zinc binding protein which is neutrophil-derived. It represents 60% of cytosolic proteins in granulocytes and is a measurement of neutrophil migration to the gastrointestinal tract.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.
Posted
Geometric Mean
Geometric Coefficient of Variation
fold change
Baseline, Weeks 4, 8, 12 and 16
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Secondary
Fold Change From Baseline in C-Reactive Protein (CRP) at Weeks 4, 8, 12, and 16
CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. CRP has a short half-life (19 hours) and therefore rises early after the onset of inflammation and rapidly decreases after resolution of the inflammation. It is induced by interleukin-6, TNF-alpha and other pro-inflammatory cytokines that are produced within the intestinal lamina propria.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.
Posted
Geometric Mean
Geometric Coefficient of Variation
fold change
Baseline, Weeks 4, 8, 12 and 16
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Secondary
Percentage of Participants With Rectal Bleeding Mayo Subscore of Zero at Weeks 4, 8, 12, and 16
Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes).
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.
Posted
Number
percentage of participants
Week 4, 8, 12 and 16
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Secondary
Percentage of Participants in Endoscopic Remission at Week 8
Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding). Endoscopic remission is defined as modified Baron Endoscopic Score equal to 0.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.
Posted
Number
percentage of participants
Week 8
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Secondary
Percentage of Participants in Clinical Remission at Week 8
Clinical remission is defined as a total Mayo score of 2 points or lower, with no individual subscores exceeding 1 point.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.
Posted
Number
percentage of participants
Week 8
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Secondary
Percentage of Participants With Decrease From Baseline of at Least 1 Point in Rectal Bleeding Mayo Subscore at Weeks 4, 8, 12, and 16
Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes). A decrease from baseline score indicates improvement.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.
Posted
Number
percentage of participants
Baseline, Weeks 4, 8, 12 and 16
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Secondary
Percentage of Participants With Endoscopic Response at Week 8
Endoscopic response is defined as a decrease in modified Baron endoscopic score from baseline of at least 2 points.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.
Posted
Number
percentage of participants
Week 8
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Secondary
Percentage of Participants in Clinical Response at Week 8
Clinical response is defined as a decrease in total Mayo score from baseline of at least 3 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.
Posted
Number
percentage of participants
Week 8
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Secondary
Change From Baseline in Total Mayo Scores at Week 8
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis, with total score ranging from 0 to 12. It consists of 4 subscores (stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and physician global assessment [PGA]), each graded from 0 to 3, with higher scores indicating more severe disease.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.
Posted
Mean
Standard Deviation
scores on a scale
Baseline, Week 8
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Secondary
Change From Baseline in Partial Mayo Scores at Weeks 4, 8, 12, and 16
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo Score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. A Partial Mayo Score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Higher scores indicate more severe disease.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.
Posted
Mean
Standard Deviation
scores on a scale
Baseline, Weeks 4, 8, 12 and 16
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
Secondary
Change From Baseline in Biopsy Histology Scores at Week 8
A 15 to 25 centimeter (cm) biopsy sample of inflamed mucosal tissue was taken from the worst affected area and scored using the Riley Index. The Riley Index is a histologic scoring system for the assessment of the activity and severity of ulcerative colitis, ranging from 0 to 24. It consists of 6 histologic features (acute inflammatory cell infiltrate, crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, and crypt architectural irregularities), all scored on a 4-point scale (higher scores indicate more severe disease).
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.
Posted
Mean
Standard Deviation
scores on a scale
Baseline and Week 8
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
Secondary
Change From Baseline in Patient-Reported Rectal Bleeding up to Week 16
Patient-reported diary data assessed the number of bowel movements (BM) per day when not having a flare and the presence of blood in the stools (rectal bleeding [RB]), if any.
The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.
Posted
Mean
Standard Deviation
scores on a scale
Baseline and Week 16
ID
Title
Description
OG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
OG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Time Frame
Baseline up to 28 days after last study drug administration.
Description
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another, or 1 participant may have experienced both an AE and SAE during the study. All treated participants were included in the analysis.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Cohort 1: Placebo, MultiStem 300
Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.
1
2
2
2
EG001
Cohort 2: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
0
3
3
3
EG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
0
2
0
2
EG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
3
4
3
4
EG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
0
6
5
6
EG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
7
23
18
23
EG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
4
25
16
25
EG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
5
19
15
19
EG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
4
21
18
21
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG0030 affected4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
Pancytopenia
Blood and lymphatic system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Ventricular tachycardia
Cardiac disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Colitis
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Colitis ulcerative
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Hypersensitivity
Immune system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Abdominal abscess
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Clostridium difficile colitis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Clostridium difficile infection
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Gastroenteritis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Pelvic sepsis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Perirectal abscess
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Adenocarcinoma of colon
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Epilepsy
Nervous system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Superior sagittal sinus thrombosis
Nervous system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Diastolic hypertension
Vascular disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG0030 affected4 at risk
EG0040 affected6 at risk
EG0054 affected23 at risk
EG0060 affected25 at risk
EG0072 affected19 at risk
EG0083 affected21 at risk
Lymphadenopathy
Blood and lymphatic system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Tachycardia
Cardiac disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Vertigo
Ear and labyrinth disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Cushingoid
Endocrine disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Abdominal tenderness
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Colitis ulcerative
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Defaecation urgency
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Dyspepsia
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Gastritis
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Haematochezia
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Painful defaecation
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Perianal erythema
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Rectal haemorrhage
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Tongue disorder
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Asthenia
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Chest discomfort
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Chest pain
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Chills
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Fatigue
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Influenza like illness
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Oedema peripheral
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Pain
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Pyrexia
General disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Bacteriuria
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Bronchitis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Cellulitis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Gastroenteritis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Influenza
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Pharyngitis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Sinusitis
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Contusion
Injury, poisoning and procedural complications
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Fall
Injury, poisoning and procedural complications
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Incision site pain
Injury, poisoning and procedural complications
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Laceration
Injury, poisoning and procedural complications
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Skeletal injury
Injury, poisoning and procedural complications
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Antibody test
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Bacterial test
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Blood albumin decreased
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Blood bilirubin increased
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Blood glucose increased
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Blood urine present
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
C-reactive protein increased
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Cold agglutinins
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Heart rate increased
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Prostatic specific antigen increased
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected2 at risk
EG0020 affected2 at risk
EG003
Weight decreased
Investigations
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Dehydration
Metabolism and nutrition disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Hyperglycaemia
Metabolism and nutrition disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Hypokalaemia
Metabolism and nutrition disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Costochondritis
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Muscle tightness
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Osteoarthritis
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Pain in jaw
Musculoskeletal and connective tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Amnesia
Nervous system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Dizziness
Nervous system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Epilepsy
Nervous system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Headache
Nervous system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Lethargy
Nervous system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Paraesthesia
Nervous system disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Anxiety
Psychiatric disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Confusional state
Psychiatric disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Depression
Psychiatric disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Insomnia
Psychiatric disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0011 affected3 at risk
EG0020 affected2 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Nasal congestion
Respiratory, thoracic and mediastinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA 17.1
Non-systematic Assessment
EG0001 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Dermatitis contact
Skin and subcutaneous tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Erythema
Skin and subcutaneous tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Night sweats
Skin and subcutaneous tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Pruritus
Skin and subcutaneous tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Rash macular
Skin and subcutaneous tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Skin lesion
Skin and subcutaneous tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Urticaria
Skin and subcutaneous tissue disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Ileostomy
Surgical and medical procedures
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Flushing
Vascular disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Hot flush
Vascular disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Hypertension
Vascular disorders
MedDRA 17.1
Non-systematic Assessment
EG0000 affected2 at risk
EG0010 affected3 at risk
EG0020 affected2 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Point of Contact
Title
Organization
Phone
Extension
Email
Pfizer ClinicalTrials.gov Call Center
Pfizer, Inc.
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
ID
Term
D003093
Colitis, Ulcerative
Ancestor Terms
ID
Term
D003092
Colitis
D005759
Gastroenteritis
D005767
Gastrointestinal Diseases
D004066
Digestive System Diseases
D015212
Inflammatory Bowel Diseases
D003108
Colonic Diseases
D007410
Intestinal Diseases
Browse Leaves
Not provided
Browse Branches
Not provided
1 subjects
FG0051 subjects
FG0060 subjects
FG0071 subjects
FG0081 subjects
0 subjects
FG0054 subjects
FG0062 subjects
FG0073 subjects
FG0083 subjects
2 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
1 subjects
FG0053 subjects
FG0066 subjects
FG0070 subjects
FG0083 subjects
40.0
± 14.0
BG00443.4± 12.8
BG00538.8± 13.4
BG00639.8± 12.5
BG00742.5± 15.7
BG00842.2± 13.7
1
BG0035
BG0047
BG00512
BG0063
BG0077
BG00836
Male
BG0002
BG0012
BG0025
BG0031
BG00416
BG00513
BG00616
BG00714
BG00869
0.10
± 1.134
OG001-0.30± 1.091
48
OG00140
Title
Denominators
Categories
Baseline
Title
Measurements
OG0001.42± 0.942
OG0011.23± 0.832
Change at Week 4
Title
Measurements
OG000-0.44± 0.943
OG001-0.38± 0.705
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Pooled MultiStem versus Pooled Placebo (Week 4)
Mixed Models Analysis
MMRM using data up to Week 8
0.54
1-sided p-value
Mean Difference (Final Values)
0.02
Standard Error of the Mean
0.161
2-Sided
80
-0.19
0.22
No
Superiority or Other
48
OG00140
Title
Denominators
Categories
Title
Measurements
OG000-0.46± 1.051
OG001-0.43± 0.874
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Pooled MultiStem versus Pooled Placebo (Week 8)
Mixed Models Analysis
MMRM using data up to Week 8
0.67
1-sided p-value
Mean Difference (Final Values)
0.08
Standard Error of the Mean
0.174
2-Sided
80
-0.15
0.30
No
Superiority or Other
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
AEs
Title
Measurements
OG0002
OG0013
OG0020
OG0034
OG0045
OG00520
OG00618
OG00716
OG00819
SAEs
Title
Measurements
OG0001
OG0010
OG0020
OG003
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
BLOOD AND LYMPHATIC SYSTEM DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0055
OG0060
OG0073
OG0084
CARDIAC DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
EAR AND LABYRINTH DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
ENDOCRINE DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
EYE DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
GASTROINTESTINAL DISORDERS
Title
Measurements
OG0002
OG0011
OG0020
OG003
GENERAL DISORDERS
Title
Measurements
OG0002
OG0011
OG0020
OG003
IMMUNE SYSTEM DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
INFECTIONS AND INFESTATIONS
Title
Measurements
OG0001
OG0011
OG0020
OG003
INJURY, POISONING AND PROCEDURAL COMPLICATIONS
Title
Measurements
OG0000
OG0011
OG0020
OG003
INVESTIGATIONS
Title
Measurements
OG0000
OG0011
OG0020
OG003
METABOLISM AND NUTRITION DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS
Title
Measurements
OG0000
OG0012
OG0020
OG003
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED
Title
Measurements
OG0000
OG0010
OG0020
OG003
NERVOUS SYSTEM DISORDERS
Title
Measurements
OG0000
OG0011
OG0020
OG003
PSYCHIATRIC DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
RENAL AND URINARY DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
Title
Measurements
OG0001
OG0011
OG0020
OG003
SKIN AND SUBCUTANEOUS TISSUE DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
SURGICAL AND MEDICAL PROCEDURES
Title
Measurements
OG0000
OG0010
OG0020
OG003
VASCULAR DISORDERS
Title
Measurements
OG0000
OG0010
OG0020
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Mild AEs
Title
Measurements
OG0006
OG00116
OG0020
OG0038
OG00413
OG00561
OG00635
OG00756
OG00848
Moderate AEs
Title
Measurements
OG0004
OG0010
OG0020
OG003
Severe AEs
Title
Measurements
OG0001
OG0010
OG0020
OG003
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Change at Week 12 (n=0,0,0,0,0,22,25,17,19)
Title
Measurements
OG000NA± NANo participants were analyzed in this arm at Week 12.
OG001NA± NANo participants were analyzed in this arm at Week 12.
OG002NA± NANo participants were analyzed in this arm at Week 12.
OG003NA± NANo participants were analyzed in this arm at Week 12.
OG004NA± NANo participants were analyzed in this arm at Week 12.
OG005-0.77± 0.869
OG006-0.64± 1.114
OG007-0.53± 0.874
OG008-0.47± 0.905
Change at Week 16 (n=2,3,2,4,6,21,24,17,19)
Title
Measurements
OG000-1.50± 0.707
OG001-1.00± 1.000
OG0020.00± 0.000
OG003
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Normal/Abnormal Baseline(n=2,3,2,4,6,23,25,19,21)
Title
Measurements
OG0002
OG0012
OG0021
OG0034
OG0044
OG00514
OG00620
OG00715
OG00817
Normal Baseline (n=2,3,2,4,6,23,25,19,21)
Title
Measurements
OG0002
OG0012
OG0021
OG003
Abnormal Baseline (n=2,3,2,2,3,22,19,15,18)
Title
Measurements
OG0001
OG0011
OG0021
OG003
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Supine SBP <90 mm Hg
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0042
OG0050
OG0060
OG0070
OG0080
Supine DBP <50 mm Hg
Title
Measurements
OG0000
OG0010
OG0020
OG003
Supine Pulse Rate <40 bpm
Title
Measurements
OG0000
OG0010
OG0020
OG003
Supine Pulse Rate >120 bpm
Title
Measurements
OG0000
OG0010
OG0020
OG003
Supine SBP >=30 mm Hg Increase From Baseline
Title
Measurements
OG0000
OG0010
OG0020
OG003
Supine DBP >=20 mm Hg Increase From Baseline
Title
Measurements
OG0002
OG0010
OG0020
OG003
Supine SBP >=30 mm Hg Decrease From Baseline
Title
Measurements
OG0000
OG0010
OG0020
OG003
Supine DBP >=20 mm Hg Decrease From Baseline
Title
Measurements
OG0001
OG0011
OG0020
OG003
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Baseline (n=2,3,1,4,5,21,23,19,20)
Title
Measurements
OG000690.7549± 17
OG0011189.8169± 22
OG002739.2300± NAOnly 1 participant was analyzed.
OG003898.2758± 89
OG004874.1363± 1462
OG005576.5796± 237
OG006476.1504± 222
OG007513.2139± 208
OG008821.1953± 220
Change at Week 4 (n=2,3,1,3,5,20,21,18,19)
Title
Measurements
OG0000.6297± 50
OG0011.8680± 103
OG0022.0264± NAOnly 1 participant was analyzed.
OG003
Change at Week 8 (n=1,2,1,3,2,18,20,17,20)
Title
Measurements
OG0002.4504± NAOnly 1 participant was analyzed.
OG0012.4559± 51
OG0022.6199± NAOnly 1 participant was analyzed.
OG003
Change at Week 12 (n=0,0,0,0,0,20,21,17,18)
Title
Measurements
OG000NA± NANo participants were analyzed in this arm at Week 12.
OG001NA± NANo participants were analyzed in this arm at Week 12.
OG002NA± NANo participants were analyzed in this arm at Week 12.
OG003
Change at Week 16 (n=2,3,1,4,4,18,18,16,17)
Title
Measurements
OG0002.1672± 49
OG0010.7679± 32
OG0021.1956± NAOnly 1 participant was analyzed.
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 4)
Mixed Models Analysis
MMRM using data up to Week 16
0.53
1-sided p-value
Geometric Mean Ratio
1.02
2-Sided
80
0.73
1.42
No
Superiority or Other
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 8)
Mixed Models Analysis
MMRM using data up to Week 16
0.91
1-sided p-value
Geometric Mean Ratio
1.48
2-Sided
80
1.02
2.14
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.81
1-sided p-value
Geometric Mean Ratio
1.38
2-Sided
80
0.86
2.23
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.44
1-sided p-value
Geometric Mean Ratio
0.94
2-Sided
80
0.59
1.51
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.67
1-sided p-value
Geometric Mean Ratio
1.18
2-Sided
80
0.72
1.94
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.62
1-sided p-value
Geometric Mean Ratio
1.12
2-Sided
80
0.68
1.84
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.95
1-sided p-value
Geometric Mean Ratio
0.95
2-Sided
80
0.58
1.57
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.30
1-sided p-value
Geometric Mean Ratio
0.81
2-Sided
80
0.49
1.36
No
Superiority or Other
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Baseline (n=2,3,2,4,6,22,25,19,20)
Title
Measurements
OG0001.272± 45
OG0011.527± 118
OG0020.229± 34
OG0030.578± 37
OG0040.180± 74
OG0050.613± 339
OG0060.542± 236
OG0070.397± 157
OG0080.453± 297
Change at Week 4 (n=2,3,2,3,6,21,25,18,20)
Title
Measurements
OG0000.289± 9
OG0010.555± 82
OG0021.937± 42
OG003
Change at Week 8 (n=1,3,1,3,5,21,25,19,20)
Title
Measurements
OG0001.390± NAOnly 1 participant was analyzed.
OG0010.745± 49
OG0022.331± NAOnly 1 participant was analyzed.
OG003
Change at Week 12 (n=0,0,0,0,0,21,24,17,18)
Title
Measurements
OG000NA± NANo participants were analyzed in this arm at Week 12.
OG001NA± NANo participants were analyzed in this arm at Week 12.
OG002NA± NANo participants were analyzed in this arm at Week 12.
OG003
Change at Week 16 (n=2,3,2,4,5,20,24,17,18)
Title
Measurements
OG0000.956± 164
OG0010.481± 56
OG0020.606± 248
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 4)
Mixed Models Analysis
MMRM using data up to Week 16
0.79
1-sided p-value
Geometric Mean Ratio
1.17
2-Sided
80
0.91
1.51
No
Superiority or Other
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 8)
Mixed Models Analysis
MMRM using data up to Week 16
0.80
1-sided p-value
Geometric Mean Ratio
1.21
2-Sided
80
0.90
1.63
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.99
1-sided p-value
Geometric Mean Ratio
2.75
2-Sided
80
1.63
4.64
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.96
1-sided p-value
Geometric Mean Ratio
1.96
2-Sided
80
1.19
3.25
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.95
1-sided p-value
Geometric Mean Ratio
1.98
2-Sided
80
1.15
3.41
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.99
1-sided p-value
Geometric Mean Ratio
2.30
2-Sided
80
1.52
3.48
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.62
1-sided p-value
Geometric Mean Ratio
1.10
2-Sided
80
0.74
1.63
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.89
1-sided p-value
Geometric Mean Ratio
1.51
2-Sided
80
0.98
2.32
No
Superiority or Other
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Week 4
Title
Measurements
OG00050.0
OG00166.7
OG00250.0
OG00333.3
OG00440.0
OG00552.2
OG00628.0
OG00731.6
OG00842.9
Week 8
Title
Measurements
OG00050.0
OG00166.7
OG00250.0
OG003
Week 12
Title
Measurements
OG000NANo participants were analyzed in this arm at Week 12.
OG001NANo participants were analyzed in this arm at Week 12.
OG002NANo participants were analyzed in this arm at Week 12.
OG003
Week 16
Title
Measurements
OG00050.0
OG001100
OG00250.0
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 4)
Regression, Logistic
0.34
1-sided p-value
Odds Ratio (OR)
1.21
2-Sided
80
0.66
2.19
No
Superiority or Other
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 8)
Regression, Logistic
0.33
1-sided p-value
Odds Ratio (OR)
1.23
2-Sided
80
0.68
2.23
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 12)
Regression, Logistic
0.10
1-sided p-value
Odds Ratio (OR)
2.37
2-Sided
80
0.99
5.67
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 12)
Regression, Logistic
0.74
1-sided p-value
Odds Ratio (OR)
0.66
2-Sided
80
0.28
1.55
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 12)
Regression, Logistic
0.48
1-sided p-value
Odds Ratio (OR)
1.04
2-Sided
80
0.41
2.64
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 16)
Regression, Logistic
0.58
1-sided p-value
Odds Ratio (OR)
0.88
2-Sided
80
0.38
2.03
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 16)
Regression, Logistic
0.68
1-sided p-value
Odds Ratio (OR)
0.74
2-Sided
80
0.33
1.66
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 16)
Regression, Logistic
0.84
1-sided p-value
Odds Ratio (OR)
0.51
2-Sided
80
0.21
1.23
No
Superiority or Other
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG00416.7
OG0054.3
OG0064.0
OG0070
OG0089.5
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo
Regression, Logistic
0.57
1-sided p-value
Odds Ratio (OR)
0.83
2-Sided
80
0.22
3.07
No
Superiority or Other
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0050
OG0068.0
OG0070
OG00819.0
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo
Regression, Logistic
0.85
1-sided p-value
Odds Ratio (OR)
0.39
2-Sided
80
0.12
1.23
No
Superiority or Other
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Week 4
Title
Measurements
OG000100
OG00166.7
OG0020
OG0030
OG00440.0
OG00543.5
OG00648.0
OG00721.1
OG00838.1
Week 8
Title
Measurements
OG000100
OG00133.3
OG0020
OG003
Week 12
Title
Measurements
OG000NANo participants were analyzed in this arm at Week 12.
OG001NANo participants were analyzed in this arm at Week 12.
OG002NANo participants were analyzed in this arm at Week 12.
OG003
Week 16
Title
Measurements
OG000100
OG00166.7
OG0020
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 4)
Regression, Logistic
0.05
1-sided p-value
Odds Ratio (OR)
2.27
2-Sided
80
1.21
4.24
No
Superiority or Other
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 8)
Regression, Logistic
0.43
1-sided p-value
Odds Ratio (OR)
1.09
2-Sided
80
0.61
1.95
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 12)
Regression, Logistic
0.44
1-sided p-value
Odds Ratio (OR)
1.11
2-Sided
80
0.45
2.76
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 12)
Regression, Logistic
0.38
1-sided p-value
Odds Ratio (OR)
1.23
2-Sided
80
0.50
3.04
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 12)
Regression, Logistic
0.89
1-sided p-value
Odds Ratio (OR)
0.38
2-Sided
80
0.14
1.04
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 16)
Regression, Logistic
0.47
1-sided p-value
Odds Ratio (OR)
1.05
2-Sided
80
0.45
2.42
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 16)
Regression, Logistic
0.24
1-sided p-value
Odds Ratio (OR)
1.58
2-Sided
80
0.70
3.57
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 16)
Regression, Logistic
0.81
1-sided p-value
Odds Ratio (OR)
0.53
2-Sided
80
0.22
1.32
No
Superiority or Other
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0058.7
OG0068.0
OG00710.5
OG00819.0
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo
Regression, Logistic
0.84
1-sided p-value
Odds Ratio (OR)
0.49
2-Sided
80
0.20
1.24
No
Superiority or Other
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Title
Measurements
OG00050.0
OG00133.3
OG0020
OG0030
OG0040
OG0054.3
OG00624.0
OG00715.8
OG00842.9
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo
Regression, Logistic
0.96
1-sided p-value
Odds Ratio (OR)
0.30
2-Sided
80
0.12
0.73
No
Superiority or Other
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Baseline (n=2,3,2,4,6,23,25,19,21)
Title
Measurements
OG00010.00± 2.828
OG0017.33± 1.155
OG0028.50± 0.707
OG0037.75± 0.957
OG0047.50± 2.258
OG0058.74± 1.839
OG0068.48± 2.143
OG0078.47± 1.806
OG0088.14± 2.220
Change at Week 8 (n=2,3,2,3,5,23,25,19,21)
Title
Measurements
OG000-2.00± 1.414(-1.84 to 0.33)
OG0010.00± 2.646(-2.32 to -0.30)
OG0021.00± 1.414(-2.11 to 0.18)
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo
ANCOVA
0.87
1-sided p-value
Mean Difference (Final Values)
0.58
Standard Error of the Mean
0.513
2-Sided
80
-0.08
1.24
No
Superiority or Other
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Baseline (n=2,3,2,4,6,23,25,19,21)
Title
Measurements
OG0007.50± 2.121
OG0015.33± 0.577
OG0026.00± 1.414
OG0035.75± 0.500
OG0045.50± 1.378
OG0056.22± 1.347
OG0066.08± 1.605
OG0076.00± 1.202
OG0085.71± 1.736
Change at Week 4 (n=2,3,2,3,5,23,25,19,21)
Title
Measurements
OG000-3.00± 0.000(-1.84 to 0.33)
OG001-2.00± 1.732(-2.32 to -0.30)
OG002-0.50± 0.707(-2.11 to 0.18)
OG003
Change at Week 8 (n=2,3,2,3,5,23,25,19,21)
Title
Measurements
OG000-2.00± 1.414
OG001-1.00± 1.732
OG0020.50± 0.707
OG003
Change at Week 12 (n=0,0,0,0,0,22,25,17,19)
Title
Measurements
OG000NA± NANo participants were analyzed in this arm at Week 12.
OG001NA± NANo participants were analyzed in this arm at Week 12.
OG002NA± NANo participants were analyzed in this arm at Week 12.
OG003
Change at Week 16 (2,3,2,4,5,21,24,17,19)
Title
Measurements
OG000-1.50± 0.707
OG001-3.00± 3.000
OG002-1.00± 2.828
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 4)
Mixed Models Analysis
MMRM using data up to Week 16
0.80
1-sided p-value
Mean Difference (Final Values)
0.29
Standard Error of the Mean
0.345
2-Sided
80
-0.15
0.74
No
Superiority or Other
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 8)
Mixed Models Analysis
MMRM using data up to Week 16
0.77
1-sided p-value
Mean Difference (Final Values)
0.30
Standard Error of the Mean
0.418
2-Sided
80
-0.23
0.84
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.74
1-sided p-value
Mean Difference (Final Values)
0.44
Standard Error of the Mean
0.666
2-Sided
80
-0.42
1.30
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.88
1-sided p-value
Mean Difference (Final Values)
0.76
Standard Error of the Mean
0.645
2-Sided
80
-0.08
1.59
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.72
1-sided p-value
Mean Difference (Final Values)
0.42
Standard Error of the Mean
0.705
2-Sided
80
-0.50
1.33
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.97
1-sided p-value
Mean Difference (Final Values)
1.21
Standard Error of the Mean
0.656
2-Sided
80
0.37
2.06
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.75
1-sided p-value
Mean Difference (Final Values)
0.43
Standard Error of the Mean
0.635
2-Sided
80
-0.39
1.25
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.85
1-sided p-value
Mean Difference (Final Values)
0.73
Standard Error of the Mean
0.692
2-Sided
80
-0.16
1.63
No
Superiority or Other
OG002
Cohort 1: MultiStem 300, Placebo
Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
Baseline(n=2,3,2,4,5,22,24,18,21)
Title
Measurements
OG0009.0± 1.41
OG0019.7± 3.79
OG00211.0± 2.83
OG0037.0± 3.92
OG00410.8± 3.77
OG0059.4± 4.37
OG00610.4± 4.24
OG0079.9± 4.17
OG0089.7± 5.14
Change at Week 4 (n=2,3,1,3,5,21,24,15,20)
Title
Measurements
OG000-3.5± 4.95(-1.84 to 0.33)
OG0011.3± 1.15(-2.32 to -0.30)
OG002-3.0± NA(-2.11 to 0.18)No standard deviation was calculated, as only 1 participant was analyzed.
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo
ANCOVA
0.75
1-sided p-value
Mean Difference (Final Values)
0.52
Standard Error of the Mean
0.753
2-Sided
80
-0.46
1.49
No
Superiority or Other
OG003
Cohort 1: MultiStem 300 (x3), Placebo
Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.
OG004
Cohort 2: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG005
Cohort 3: MultiStem 750, MultiStem 750
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG006
Cohort 3: MultiStem 750, Placebo
Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
OG007
Cohort 3: Placebo, MultiStem 750
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.
OG008
Cohort 3: Placebo, Placebo
Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.
Units
Counts
Participants
OG0002
OG0013
OG0022
OG0034
OG0046
OG00523
OG00625
OG00719
OG00821
Title
Denominators
Categories
BM: Baseline(n=2,3,2,4,6,23,25,19,21)
Title
Measurements
OG00012.50± 4.950
OG0018.00± 2.784
OG0026.75± 2.475
OG00311.75± 10.508
OG0048.42± 3.089
OG0057.50± 3.490
OG0067.78± 3.781
OG0077.50± 3.571
OG0086.88± 4.886
BM: Change at Week 1 (n=2,3,2,4,5,23,25,19,21)
Title
Measurements
OG000-1.60± 2.263(-1.84 to 0.33)
OG001-1.89± 1.766(-2.32 to -0.30)
OG0024.15± 2.845(-2.11 to 0.18)
OG003
BM: Change at Week 4 (n=2,2,2,3,5,23,23,16,19
Title
Measurements
OG000-1.43± 3.435
OG001-1.89± 5.101
OG0022.36± 0.505
OG003
BM: Change at Week 8 (n=2,3,2,3,6,23,23,16,19)
Title
Measurements
OG000-1.67± 3.771
OG001-0.86± 3.517
OG0023.18± 0.758
OG003
BM: Change at Week 12 (n=1,1,1,2,2,21,25,16,18)
Title
Measurements
OG0000.14± NANo standard deviation was calculated as only 1 participant was analyzed.
OG0011.43± NANo standard deviation was calculated as only 1 participant was analyzed.
OG0021.57± NANo standard deviation was calculated as only 1 participant was analyzed.
OG003
BM: Change at Week 16 (n=1,3,2,3,4,22,24,16,18)
Title
Measurements
OG0000.00± NANo standard deviation was calculated as only 1 participant was analyzed.
OG001-2.51± 3.716
OG0021.72± 0.596
OG003
RB: Baseline (n=2,3,2,4,6,23,25,19,21)
Title
Measurements
OG0001.25± 1.061
OG0011.17± 1.258
OG0021.00± 1.414
OG003
RB: Change at Week 1 (n=2,3,2,4,5,23,25,19,21)
Title
Measurements
OG000-0.32± 0.253
OG001-1.00± 1.167
OG002-0.33± 0.471
OG003
RB: Change at Week 4 (n=2,2,2,3,5,23,23,16,19)
Title
Measurements
OG000-0.75± 0.354
OG001-0.29± 1.010
OG002-0.25± 0.354
OG003
RB: Change at Week 8 (n=2,3,2,3,6,22,23,13,20)
Title
Measurements
OG000-0.75± 0.354
OG001-0.50± 0.500
OG0020.00± 0.000
OG003
RB: Change at Week 12 (n=1,1,1,2,2,21,25,16,18)
Title
Measurements
OG000-0.57± NANo standard deviation was calculated as only 1 participant was analyzed.
OG0010.00± NANo standard deviation was calculated as only 1 participant was analyzed.
OG0020.00± NANo standard deviation was calculated as only 1 participant was analyzed.
OG003
RB: Change at Week 16 (n=1,3,2,3,4,22,24,16,18)
Title
Measurements
OG000-1.00± NANo standard deviation was calculated as only 1 participant was analyzed.
OG001-1.17± 1.258
OG002-0.10± 0.141
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 4)
Mixed Models Analysis
MMRM using data up to Week 16
0.51
1-sided p-value
Mean Difference (Final Values)
0.00
Standard Error of the Mean
0.144
2-Sided
80
-0.18
0.19
No
Superiority or Other
OG005
OG006
OG007
OG008
Pooled MultiStem versus Pooled Placebo (Week 8)
Mixed Models Analysis
MMRM using data up to Week 16
0.62
1-sided p-value
Mean Difference (Final Values)
0.05
Standard Error of the Mean
0.158
2-Sided
80
-0.16
0.25
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.29
1-sided p-value
Mean Difference (Final Values)
-0.12
Standard Error of the Mean
0.213
2-Sided
80
-0.39
0.16
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.74
1-sided p-value
Mean Difference (Final Values)
0.13
Standard Error of the Mean
0.209
2-Sided
80
-0.14
0.40
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 12)
Mixed Models Analysis
MMRM using data up to Week 16
0.36
1-sided p-value
Mean Difference (Final Values)
-0.08
Standard Error of the Mean
0.226
2-Sided
80
-0.37
0.21
No
Superiority or Other
OG005
OG008
Cohort 3 MM versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.56
1-sided p-value
Mean Difference (Final Values)
0.04
Standard Error of the Mean
0.234
2-Sided
80
-0.26
0.34
No
Superiority or Other
OG006
OG008
Cohort 3 MP versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.18
1-sided p-value
Mean Difference (Final Values)
-0.21
Standard Error of the Mean
0.231
2-Sided
80
-0.51
0.09
No
Superiority or Other
OG007
OG008
Cohort 3 PM versus Cohort 3 PP (Week 16)
Mixed Models Analysis
MMRM using data up to Week 16
0.31
1-sided p-value
Mean Difference (Final Values)
-0.12
Standard Error of the Mean
0.250
2-Sided
80
-0.45
0.20
No
Superiority or Other
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0055 affected23 at risk
EG0061 affected25 at risk
EG0072 affected19 at risk
EG0083 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0062 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0053 affected23 at risk
EG0062 affected25 at risk
EG0071 affected19 at risk
EG0082 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0055 affected23 at risk
EG0062 affected25 at risk
EG0073 affected19 at risk
EG0085 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0053 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0042 affected6 at risk
EG0053 affected23 at risk
EG0061 affected25 at risk
EG0071 affected19 at risk
EG0082 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0072 affected19 at risk
EG0080 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0053 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0072 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0070 affected19 at risk
EG0081 affected21 at risk
2 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0052 affected23 at risk
EG0063 affected25 at risk
EG0071 affected19 at risk
EG0082 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0061 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0082 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
3 affected
4 at risk
EG0040 affected6 at risk
EG0052 affected23 at risk
EG0062 affected25 at risk
EG0071 affected19 at risk
EG0082 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0052 affected23 at risk
EG0061 affected25 at risk
EG0075 affected19 at risk
EG0084 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0053 affected23 at risk
EG0062 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
1 affected
4 at risk
EG0041 affected6 at risk
EG0052 affected23 at risk
EG0062 affected25 at risk
EG0071 affected19 at risk
EG0081 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0052 affected23 at risk
EG0062 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
0 at risk
EG0040 affected1 at risk
EG0050 affected16 at risk
EG0060 affected13 at risk
EG0070 affected16 at risk
EG0081 affected14 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0052 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0081 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0052 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0062 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0053 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0053 affected23 at risk
EG0061 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0072 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0063 affected25 at risk
EG0077 affected19 at risk
EG0086 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0072 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0073 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0082 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0071 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0053 affected23 at risk
EG0063 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0061 affected25 at risk
EG0070 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0063 affected25 at risk
EG0070 affected19 at risk
EG0081 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0051 affected23 at risk
EG0062 affected25 at risk
EG0071 affected19 at risk
EG0081 affected21 at risk
1 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0081 affected21 at risk
0 affected
4 at risk
EG0041 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0070 affected19 at risk
EG0080 affected21 at risk
0 affected
4 at risk
EG0040 affected6 at risk
EG0050 affected23 at risk
EG0060 affected25 at risk
EG0071 affected19 at risk
EG0080 affected21 at risk
3
OG0040
OG0057
OG0064
OG0075
OG0084
0
OG0040
OG0051
OG0060
OG0071
OG0081
0
OG0040
OG0051
OG0060
OG0071
OG0081
0
OG0040
OG0050
OG0061
OG0071
OG0080
0
OG0040
OG0051
OG0060
OG0070
OG0083
2
OG0044
OG00513
OG00610
OG00711
OG00812
3
OG0041
OG0058
OG0065
OG0075
OG0086
1
OG0040
OG0050
OG0062
OG0070
OG0080
1
OG0041
OG00510
OG0069
OG0079
OG0087
1
OG0040
OG0052
OG0062
OG0072
OG0081
0
OG0041
OG0054
OG0061
OG0075
OG0083
1
OG0040
OG0052
OG0060
OG0071
OG0081
0
OG0042
OG0056
OG0065
OG0072
OG0081
0
OG0040
OG0051
OG0060
OG0070
OG0080
1
OG0041
OG0051
OG0063
OG0079
OG0086
0
OG0040
OG0051
OG0061
OG0073
OG0082
0
OG0040
OG0051
OG0061
OG0070
OG0080
0
OG0040
OG0055
OG0065
OG0071
OG0084
1
OG0041
OG0054
OG0064
OG0073
OG0082
0
OG0040
OG0051
OG0060
OG0071
OG0080
0
OG0042
OG0051
OG0061
OG0072
OG0081
5
OG0042
OG00533
OG00631
OG00721
OG00817
4
OG0040
OG00513
OG0068
OG0074
OG0083
0.00
± 0.816
OG004-0.60± 1.140
OG005-0.57± 0.978
OG006-0.92± 1.100
OG007-0.47± 0.874
OG008-0.58± 0.838
3
OG0044
OG0059
OG00616
OG00712
OG00813
1
OG0042
OG0057
OG0064
OG0074
OG0086
0
OG0040
OG0050
OG0061
OG0070
OG0080
0
OG0040
OG0050
OG0060
OG0070
OG0080
0
OG0040
OG0053
OG0060
OG0071
OG0080
1
OG0041
OG0051
OG0063
OG0071
OG0082
1
OG0040
OG0053
OG0060
OG0072
OG0084
1
OG0040
OG0051
OG0061
OG0071
OG0081
0
OG0040
OG0056
OG0061
OG0073
OG0080
2.0549
± 112
OG0041.0940± 91
OG0051.2196± 158
OG0060.8179± 314
OG0071.0541± 166
OG0080.6722± 193
0.5744
± 52
OG0040.3282± 2
OG0051.0704± 220
OG0060.7462± 235
OG0070.8598± 227
OG0080.3479± 242
NA
± NA
No participants were analyzed in this arm at Week 12.
OG004NA± NANo participants were analyzed in this arm at Week 12.
OG0050.9947± 171
OG0060.8269± 310
OG0070.8788± 293
OG0080.5279± 171
0.4459
± 139
OG0040.2474± 4517
OG0050.6473± 277
OG0060.8486± 149
OG0070.5473± 309
OG0080.5275± 243
1.285
± 60
OG0041.446± 54
OG0050.891± 147
OG0060.764± 140
OG0070.999± 103
OG0080.588± 132
1.172
± 20
OG0041.555± 31
OG0051.189± 146
OG0060.759± 207
OG0071.200± 113
OG0080.623± 150
NA
± NA
No participants were analyzed in this arm at Week 12.
OG004NA± NANo participants were analyzed in this arm at Week 12.
OG0050.937± 211
OG0060.710± 365
OG0070.782± 149
OG0080.373± 155
0.869
± 14
OG0041.184± 54
OG0050.776± 156
OG0060.425± 176
OG0070.612± 133
OG0080.417± 197
33.3
OG00440.0
OG00547.8
OG00636.0
OG00731.6
OG00847.6
NA
No participants were analyzed in this arm at Week 12.
OG004NANo participants were analyzed in this arm at Week 12.
OG00560.9
OG00640.0
OG00747.4
OG00842.9
50.0
OG00440.0
OG00547.8
OG00648.0
OG00736.8
OG00852.4
0
OG00440.0
OG00534.8
OG00648.0
OG00731.6
OG00847.6
NA
No participants were analyzed in this arm at Week 12.
OG004NANo participants were analyzed in this arm at Week 12.
OG00554.5
OG00660.0
OG00741.2
OG00852.6
25.0
OG00460.0
OG00547.6
OG00658.3
OG00735.3
OG00847.4
0.33
± 0.577
(-3.37 to -1.15)
OG004-0.60± 0.894
OG005-0.78± 2.088
OG006-1.20± 2.872
OG007-0.89± 2.132
OG008-2.00± 2.683
0.67
± 1.528
(-3.37 to -1.15)
OG004-0.40± 1.140
OG005-1.00± 1.414
OG006-0.96± 1.791
OG007-1.16± 1.675
OG008-1.24± 1.895
0.33
± 0.577
OG004-0.80± 1.095
OG005-0.91± 1.756
OG006-1.12± 2.472
OG007-0.79± 1.653
OG008-1.62± 2.037
NA
± NA
No participants were analyzed in this arm at Week 12.
OG004NA± NANo participants were analyzed in this arm at Week 12.